



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

January 2019





HIV/AIDS Drug Treatment Program

Monthly Report

© 2019 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
608 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8202
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.cfenet.ubc.ca
Email: info@cfenet.ubc.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS



This document is best viewed in colour.
Drug definitions available in the back.



EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

January 2019

N = 7392



Health Authority	Male	Female	All
FRASER	1439	423	1862
INTERIOR	398	98	496
NORTHERN	124	78	202
VANCOUVER COASTAL	3421	466	3887
VANCOUVER ISLAND	754	154	908
	6136	1219	7355
		Unknown/not stated:	37
		Total:	7392

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (January 2014 - January 2019)






1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (January 2014 - January 2019)






1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants
(January 2014 - January 2019)






1.5 BC-CfE Enrollment: New Antiretroviral Participants (January 2014 - January 2019)






1.6 Percent Distribution of Active Participants by CD4 Count (January 2014 - January 2019)






1.7 Percent Distribution of Inactive Participants by CD4 Count (January 2014 - January 2019)





1.8 Active and Inactive Participants
(January 2014 - January 2019)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (January 2014 - January 2019)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (January 2014 - January 2019)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(January 2014 - January 2019)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (January 2014 - January 2019)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(January 2014 - January 2019)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (January 2014 - January 2019)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(January 2014 - January 2019)





1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (January 2014 - January 2019)




Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes





1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(January 2014 - January 2019)




Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes






1.18 Baseline CD4 for Antiretroviral First Starts
(January 2014 - January 2019)






**1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
(January 2014 - January 2019)**






1.20 Cumulative Resistance Testing Results by Resistance Category (January 2014 - January 2019)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (January 2014 - January 2019)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2019
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	26	5	0	5	5	700	5	<40	3
1988	28	7	0	7	7	530	7	<40	3
1989	26	54	1	55	44	485	54	<40	3
1990	24	55	1	56	51	510	56	<40	3
1991	25	37	3	40	31	580	40	<40	3
1992	24	63	5	68	50	560	66	<40	3
1993	23	137	16	153	146	555	151	<40	3
1994	22	83	13	96	78	555	92	<40	3
1995	22	132	23	155	126	560	149	<40	3
1996	20	357	58	415	354	580	397	<40	3
1997	18	296	34	330	297	650	320	<40	3
1998	17	201	46	247	212	580	234	<40	3
1999	17	167	40	207	183	590	198	<40	3
2000	17	130	34	164	145	570	156	<40	3
2001	17	125	29	154	129	570	148	<40	3
2002	16	125	27	152	121	610	140	<40	3
2003	15	160	29	189	163	630	184	<40	3
2004	14	166	40	206	171	600	197	<40	3
2005	13	192	46	238	206	620	222	<40	3
2006	12	199	44	243	202	605	231	<40	3
2007	11	254	52	306	262	600	291	<40	3
2008	10	296	69	365	309	620	347	<40	3
2009	9	329	74	403	335	650	377	<40	3
2010	8	287	69	356	301	640	336	<40	3
2011	7	337	74	411	358	680	390	<40	3
2012	6	280	64	344	289	700	324	<40	3
2013	5	279	67	346	291	680	328	<40	3
2014	5	294	52	346	278	700	328	<40	3
2015	4	293	49	342	291	650	327	<40	3
2016	3	288	57	345	295	650	321	<40	3
2017	2	248	39	287	249	640	274	<40	3
2018	1	246	59	305	266	567	298	<40	3
2019	0	26	7	33	28	415	30	3068	3
Total:		6148	1221	7369					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2018	7294	752	2386	<40	2106	610
FEB-2018	7256	764	1904	<40	1742	610
MAR-2018	7278	774	2050	<40	1827	617
APR-2018	7264	778	2082	<40	1842	620
MAY-2018	7287	778	2149	<40	1926	600
JUN-2018	7292	794	2008	<40	1790	610
JUL-2018	7298	793	2039	<40	1810	600
AUG-2018	7298	800	2093	<40	1872	618
SEP-2018	7252	804	2015	<40	1778	620
OCT-2018	7346	784	2170	<40	1930	610
NOV-2018	7353	788	2093	<40	1789	630
DEC-2018	7369	797	1750	<40	1498	620
JAN-2019	7392	801	2451	<40	1993	610

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2018	1419	3368	78	872	71	380
FEB-2018	1464	3137	79	1036	65	440
MAR-2018	1450	3236	75	59	70	485
APR-2018	1468	3174	71	808	62	484
MAY-2018	1451	3295	91	<40	82	455
JUN-2018	1459	3283	68	2980	64	440
JUL-2018	1462	3290	68	<40	53	570
AUG-2018	1496	3187	63	56	59	490
SEP-2018	1543	2987	89	181	82	415
OCT-2018	1471	3341	79	<50	67	350
NOV-2018	1476	3330	80	80	69	460
DEC-2018	1473	3353	54	359	43	450
JAN-2019	1478	3376	78	70	69	380

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2018	7252	1419	13	12	192	126	55	13218
FEB-2018	7220	1464	11	27	123	168	-32	13255
MAR-2018	7238	1450	17	21	152	134	18	13282
APR-2018	7230	1468	13	15	153	159	-8	13304
MAY-2018	7257	1451	9	12	171	144	27	13329
JUN-2018	7255	1459	13	16	148	150	-2	13351
JUL-2018	7254	1462	13	14	158	152	-1	13377
AUG-2018	7262	1496	9	27	155	161	8	13416
SEP-2018	7215	1543	16	15	154	194	-47	13442
OCT-2018	7313	1471	8	19	217	126	98	13478
NOV-2018	7329	1476	5	9	174	160	16	13504
DEC-2018	7346	1473	11	20	148	139	17	13530
JAN-2019	7369	1478	12	19	185	169	23	13564

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2018	58	6730	451	55	7294	0.80%	92.27%	6.18%	0.75%	100.00%
FEB-2018	61	6685	451	59	7256	0.84%	92.13%	6.22%	0.81%	100.00%
MAR-2018	62	6708	453	56	7279	0.85%	92.16%	6.22%	0.77%	100.00%
APR-2018	58	6699	449	58	7264	0.80%	92.22%	6.18%	0.80%	100.00%
MAY-2018	64	6711	455	58	7288	0.88%	92.08%	6.24%	0.80%	100.00%
JUN-2018	61	6724	449	58	7292	0.84%	92.21%	6.16%	0.80%	100.00%
JUL-2018	53	6729	461	55	7298	0.73%	92.20%	6.32%	0.75%	100.00%
AUG-2018	54	6734	454	56	7298	0.74%	92.27%	6.22%	0.77%	100.00%
SEP-2018	51	6684	458	59	7252	0.70%	92.17%	6.32%	0.81%	100.00%
OCT-2018	53	6763	476	54	7346	0.72%	92.06%	6.48%	0.74%	100.00%
NOV-2018	52	6774	477	50	7353	0.71%	92.13%	6.49%	0.68%	100.00%
DEC-2018	50	6791	479	49	7369	0.68%	92.16%	6.50%	0.66%	100.00%
JAN-2019	51	6802	487	52	7392	0.69%	92.02%	6.59%	0.70%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		stavudine		didanosine		tenofovir <TAF>		tenofovir <TDF>	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2018	10 36%	3320 47%	9 32%	3076 43%	1 4%	61 1%	0 0%	5 0%	0 0%	4 0%	2 7%	292 4%	16 57%	3636 51%
FEB-2018	13 35%	3321 47%	12 32%	3079 44%	0 0%	61 1%	0 0%	5 0%	0 0%	4 0%	0 0%	299 4%	25 68%	3586 51%
MAR-2018	10 37%	3340 47%	10 37%	3104 44%	0 0%	60 1%	0 0%	4 0%	0 0%	4 0%	0 0%	311 4%	17 63%	3567 50%
APR-2018	5 23%	3347 47%	5 23%	3115 44%	0 0%	56 1%	0 0%	3 0%	0 0%	4 0%	2 9%	333 5%	15 68%	3540 50%
MAY-2018	9 39%	3355 47%	8 35%	3129 44%	1 4%	57 1%	0 0%	5 0%	0 0%	4 0%	1 4%	351 5%	13 57%	3516 50%
JUN-2018	6 30%	3373 48%	6 30%	3149 45%	0 0%	54 1%	0 0%	5 0%	0 0%	3 0%	1 5%	380 5%	13 65%	3485 49%
JUL-2018	7 28%	3401 48%	7 28%	3178 45%	0 0%	51 1%	0 0%	5 0%	0 0%	3 0%	4 16%	398 6%	14 56%	3453 49%
AUG-2018	13 33%	3398 48%	14 36%	3186 45%	0 0%	50 1%	0 0%	4 0%	0 0%	3 0%	2 5%	415 6%	23 59%	3418 48%
SEP-2018	4 15%	3380 48%	3 12%	3166 45%	1 4%	47 1%	0 0%	4 0%	0 0%	2 0%	4 15%	446 6%	18 69%	3374 48%
OCT-2018	11 31%	3423 48%	9 26%	3210 45%	1 3%	49 1%	0 0%	3 0%	0 0%	2 0%	0 0%	479 7%	25 71%	3385 47%
NOV-2018	9 35%	3434 48%	8 31%	3221 45%	0 0%	47 1%	0 0%	4 0%	0 0%	2 0%	1 4%	492 7%	17 65%	3357 47%
DEC-2018	8 31%	3450 48%	8 31%	3238 45%	0 0%	45 1%	0 0%	4 0%	0 0%	1 0%	2 8%	504 7%	16 62%	3357 47%
JAN-2019	8 24%	3469 48%	7 21%	3255 45%	1 3%	45 1%	0 0%	4 0%	0 0%	1 0%	1 3%	519 7%	25 74%	3357 47%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





Monthly Report

2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)

	emtricitabine			
	Initial		All	
JAN-2018	18	64%	3712	52%
FEB-2018	24	65%	3680	52%
MAR-2018	17	63%	3673	52%
APR-2018	17	77%	3662	52%
MAY-2018	14	61%	3662	52%
JUN-2018	14	70%	3662	52%
JUL-2018	18	72%	3655	52%
AUG-2018	25	64%	3651	52%
SEP-2018	22	85%	3633	52%
OCT-2018	24	69%	3685	52%
NOV-2018	17	65%	3673	51%
DEC-2018	18	69%	3677	51%
JAN-2019	26	76%	3697	51%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	(fos)amprenavir		atazanavir		darunavir		lopinavir		nelfinavir		ritonavir		saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2018	0 0%	8 0%	3 30%	1318 45%	7 70%	1418 48%	0 0%	196 7%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
FEB-2018	0 0%	6 0%	0 0%	1258 44%	15 100%	1422 49%	0 0%	190 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAR-2018	0 0%	7 0%	1 9%	1247 43%	10 91%	1439 50%	0 0%	188 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
APR-2018	0 0%	6 0%	0 0%	1223 43%	11 100%	1437 50%	0 0%	182 6%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAY-2018	0 0%	7 0%	0 0%	1210 43%	5 100%	1443 51%	0 0%	181 6%	0 0%	2 0%	0 0%	1 0%	0 0%	10 0%
JUN-2018	0 0%	7 0%	1 8%	1191 42%	11 92%	1434 51%	0 0%	177 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
JUL-2018	0 0%	7 0%	2 20%	1171 42%	7 70%	1443 52%	1 10%	170 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
AUG-2018	0 0%	7 0%	5 31%	1157 42%	11 69%	1426 52%	0 0%	166 6%	0 0%	1 0%	0 0%	1 0%	0 0%	8 0%
SEP-2018	0 0%	7 0%	1 14%	1134 42%	6 86%	1409 52%	0 0%	160 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
OCT-2018	0 0%	7 0%	3 17%	1123 41%	15 83%	1450 53%	0 0%	154 6%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
NOV-2018	0 0%	6 0%	1 14%	1116 41%	6 86%	1461 53%	0 0%	147 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
DEC-2018	0 0%	5 0%	1 11%	1106 41%	7 78%	1465 54%	1 11%	146 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
JAN-2019	0 0%	6 0%	1 8%	1100 40%	11 92%	1480 54%	0 0%	140 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	tipranavir			
	Initial		All	
JAN-2018	0	0%	1	0%
FEB-2018	0	0%	1	0%
MAR-2018	0	0%	1	0%
APR-2018	0	0%	1	0%
MAY-2018	0	0%	1	0%
JUN-2018	0	0%	1	0%
JUL-2018	0	0%	1	0%
AUG-2018	0	0%	1	0%
SEP-2018	0	0%	1	0%
OCT-2018	0	0%	1	0%
NOV-2018	0	0%	1	0%
DEC-2018	0	0%	1	0%
JAN-2019	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2018	3 50%	779 37%	1 17%	263 13%	2 33%	757 36%	0 0%	302 14%
FEB-2018	3 75%	771 37%	0 0%	257 12%	0 0%	749 36%	1 25%	306 15%
MAR-2018	1 33%	758 37%	0 0%	250 12%	0 0%	736 36%	2 67%	311 15%
APR-2018	1 50%	745 37%	0 0%	245 12%	0 0%	731 36%	1 50%	318 16%
MAY-2018	4 67%	725 36%	1 17%	252 12%	0 0%	727 36%	1 17%	316 16%
JUN-2018	1 50%	721 36%	0 0%	248 12%	0 0%	725 36%	1 50%	314 16%
JUL-2018	3 60%	723 36%	0 0%	243 12%	0 0%	717 36%	2 40%	314 16%
AUG-2018	2 100%	715 36%	0 0%	238 12%	0 0%	716 36%	0 0%	308 16%
SEP-2018	6 100%	707 36%	0 0%	236 12%	0 0%	712 36%	0 0%	311 16%
OCT-2018	3 60%	697 36%	0 0%	234 12%	0 0%	710 36%	2 40%	324 17%
NOV-2018	8 80%	688 35%	0 0%	230 12%	0 0%	700 36%	2 20%	323 17%
DEC-2018	1 100%	684 36%	0 0%	225 12%	0 0%	696 36%	0 0%	320 17%
JAN-2019	4 80%	668 35%	0 0%	221 12%	1 20%	695 37%	0 0%	318 17%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	bictegravir		dolutegravir		elvitegravir		maraviroc		raltegravir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2018	0 0%	0 0%	9 47%	2006 60%	8 42%	632 19%	0 0%	46 1%	2 11%	688 21%
FEB-2018	0 0%	0 0%	16 70%	2027 60%	6 26%	642 19%	0 0%	45 1%	1 4%	676 20%
MAR-2018	0 0%	0 0%	14 100%	2061 61%	0 0%	645 19%	0 0%	43 1%	0 0%	674 20%
APR-2018	0 0%	0 0%	8 67%	2106 61%	4 33%	654 19%	0 0%	44 1%	0 0%	681 20%
MAY-2018	0 0%	0 0%	13 65%	2139 61%	4 20%	665 19%	1 5%	42 1%	3 15%	675 19%
JUN-2018	0 0%	0 0%	7 64%	2174 62%	3 27%	675 19%	0 0%	42 1%	1 9%	678 19%
JUL-2018	0 0%	0 0%	7 58%	2210 62%	4 33%	676 19%	0 0%	43 1%	1 8%	677 19%
AUG-2018	0 0%	0 0%	23 79%	2256 62%	5 17%	676 19%	0 0%	42 1%	1 3%	671 19%
SEP-2018	0 0%	9 0%	5 36%	2261 62%	9 64%	690 19%	0 0%	41 1%	0 0%	656 18%
OCT-2018	0 0%	17 0%	13 76%	2320 63%	4 24%	708 19%	0 0%	40 1%	0 0%	659 18%
NOV-2018	0 0%	17 0%	11 100%	2346 63%	0 0%	705 19%	0 0%	38 1%	0 0%	651 17%
DEC-2018	0 0%	17 0%	13 72%	2369 63%	5 28%	721 19%	0 0%	39 1%	0 0%	652 17%
JAN-2019	0 0%	16 0%	15 79%	2426 63%	3 16%	731 19%	0 0%	39 1%	1 5%	648 17%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Bictegravir not currently available on BC-CfE Formulary. Drug supplied by the manufacturer for study rollover purposes





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2018	2010	27.56	1645	22.55	2596	35.59	117	1.60	55	0.75	871	11.94
FEB-2018	1968	27.12	1630	22.46	2615	36.04	116	1.60	59	0.81	868	11.96
MAR-2018	1979	27.19	1616	22.20	2647	36.36	113	1.55	56	0.77	868	11.92
APR-2018	1937	26.67	1596	21.97	2698	37.14	114	1.57	58	0.80	861	11.85
MAY-2018	1931	26.50	1575	21.61	2738	37.57	114	1.56	58	0.80	872	11.96
JUN-2018	1911	26.21	1564	21.45	2790	38.26	113	1.55	58	0.80	856	11.74
JUL-2018	1887	25.86	1567	21.47	2820	38.64	110	1.51	55	0.75	859	11.77
AUG-2018	1866	25.57	1549	21.22	2865	39.26	111	1.52	56	0.77	851	11.66
SEP-2018	1831	25.25	1533	21.14	2878	39.69	109	1.50	59	0.81	842	11.61
OCT-2018	1853	25.22	1529	20.81	2947	40.12	104	1.42	54	0.74	859	11.69
NOV-2018	1847	25.12	1524	20.73	2970	40.39	106	1.44	50	0.68	856	11.64
DEC-2018	1843	25.01	1511	20.50	3007	40.81	104	1.41	49	0.66	855	11.60
JAN-2019	1838	24.86	1480	20.02	3057	41.36	100	1.35	52	0.70	865	11.70

Definitions:

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2018	12	1	1	0	4	4	470
FEB-2018	27	3	2	2	6	13	485
MAR-2018	21	4	1	5	4	6	325
APR-2018	15	0	0	5	3	5	480
MAY-2018	12	1	0	4	3	2	370
JUN-2018	16	3	5	1	1	6	237
JUL-2018	14	4	1	3	4	1	284
AUG-2018	27	2	2	6	4	13	450
SEP-2018	15	2	3	1	3	5	405
OCT-2018	19	0	1	2	5	10	525
NOV-2018	9	2	2	2	0	2	185
DEC-2018	20	2	0	5	5	8	433
JAN-2019	19	3	3	2	4	5	380

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2018	11965	3660
FEB-2018	11994	3674
MAR-2018	12022	3703
APR-2018	12052	3732
MAY-2018	12087	3757
JUN-2018	12099	3760
JUL-2018	12125	3784
AUG-2018	12139	3779
SEP-2018	12162	3800
OCT-2018	12182	3801
NOV-2018	12220	3821
DEC-2018	12224	3815
JAN-2019	12268	3843

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved
Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
January 2019

N = 7392

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

January 2019

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

January 2019

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

January 2019

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

January 2019

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

January 2019

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





**4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
INTERIOR Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	5	5	*
	35-49	11	13	*
	50+	25	36	*
	Total HSDA:	41	54	30
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	69	92	52	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	366	489	272	
THOMPSON/CARIBOO/ SHUSWAP	0-19	*	*	0
	20-34	*	*	14
	35-49	*	*	40
	50+	*	*	88
Total HSDA:	188	251	142	
Total HA:		664	886	496

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		664	886	496

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	526	706	398
Female	138	180	98

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	496	54	590	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
INTERIOR Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	18	11
	5 years or more	7	6
	<5 years	16	13
	Total HSDA:	41	30
KOOTENAY BOUNDARY	10 years or more	43	31
	5 years or more	13	11
	<5 years	13	10
	Total HSDA:	69	52
OKANAGAN	10 years or more	224	160
	5 years or more	62	49
	<5 years	80	63
	Total HSDA:	366	272
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	103	72
	5 years or more	40	32
	<5 years	45	38
	Total HSDA:	188	142
Total HA:		664	496

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	388	274
5 years or more	122	98
<5 years	154	124
Total HA:	664	496

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	40	58	12	24
KOOTENAY BOUNDARY	68	119	22	43
OKANAGAN	210	908	62	282
THOMPSON/CARIBOO/SHUSWAP	127	489	36	134
Total:	445	1574	132	483

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	92

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		364	450
FRASER NORTH	0-19	10	10	*
	20-34	113	115	*
	35-49	347	382	*
	50+	529	844	*
	Total HSDA:		999	1351
FRASER SOUTH	0-19	7	7	5
	20-34	112	114	84
	35-49	343	392	289
	50+	513	755	432
	Total HSDA:		975	1268
Total HA:		2338	3069	1862

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	21	21	10
	20-34	255	261	184
	35-49	802	898	635
	50+	1260	1889	1033
Total HA:		2338	3069	1862

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1778	2356	1439
Female	560	713	423

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1862	51	620	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	202	155
	5 years or more	89	70
	<5 years	73	58
	Total HSDA:	364	283
FRASER NORTH	10 years or more	531	384
	5 years or more	255	207
	<5 years	213	178
	Total HSDA:	999	769
FRASER SOUTH	10 years or more	508	414
	5 years or more	224	181
	<5 years	243	215
	Total HSDA:	975	810
Total HA:		2338	1862

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	1241	953
5 years or more	568	458
<5 years	529	451
Total HA:	2338	1862

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	137	486	37	69
FRASER NORTH	246	1537	55	246
FRASER SOUTH	210	1328	45	367
Total:	593	3351	137	682

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	198
FRASER NORTH	653
FRASER SOUTH	544
Total:	1395

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	0
	20-34	*	*	19
	35-49	*	*	64
	50+	*	*	198
	Total HSDA:		329	475
RICHMOND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		168	217
VANCOUVER	0-19	34	37	6
	20-34	432	443	318
	35-49	1443	1619	1064
	50+	2741	4660	2088
	Total HSDA:	4650	6759	3476
Total HA:		5147	7451	3887

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	37	40	7
	20-34	482	494	354
	35-49	1568	1757	1163
	50+	3060	5160	2363
Total HA:		5147	7451	3887

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
	2	2	0
Male	4523	6533	3421
Female	622	916	466

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3887	53	630	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	179	150
	5 years or more	83	70
	<5 years	67	61
	Total HSDA:	329	281
RICHMOND	10 years or more	90	67
	5 years or more	39	31
	<5 years	39	32
	Total HSDA:	168	130
VANCOUVER	10 years or more	2623	1882
	5 years or more	1206	911
	<5 years	821	683
	Never on ART	0	0
	Total HSDA:	4650	3476
Total HA:	5147	3887	

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	2892	2099
	5 years or more	1328	1012
	<5 years	927	776
	Never on ART	0	0
Total HA:		5147	3887

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	166	484	51	171
RICHMOND	43	284	12	95
VANCOUVER	586	10680	196	5362
Total:	795	11448	259	5628

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	115

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	0
	20-34	*	*	19
	35-49	*	*	71
	50+	*	*	170
	Total HSDA:		314	442
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		120	160
SOUTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		718	1014
Total HA:		1152	1616	908

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	*
	20-34	102	108	*
	35-49	306	354	*
	50+	738	1148	*
Total HA:		1152	1616	908

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	948	1331	754
Female	204	285	154

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	908	54	540	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	169	140
	5 years or more	70	62
	<5 years	75	58
	Total HSDA:	314	260
NORTH VANCOUVER ISLAND	10 years or more	67	56
	5 years or more	30	22
	<5 years	23	20
	Total HSDA:	120	98
SOUTH VANCOUVER ISLAND	10 years or more	406	292
	5 years or more	153	124
	<5 years	159	134
	Total HSDA:	718	550
Total HA:		1152	908

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	642	488
	5 years or more	253	208
	<5 years	257	212
Total HA:		1152	908

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	191	834	77	190
NORTH VANCOUVER ISLAND	132	259	47	74
SOUTH VANCOUVER ISLAND	208	1744	46	557
Total:	531	2837	170	821

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	50
NORTH VANCOUVER ISLAND	36
SOUTH VANCOUVER ISLAND	103
Total:	189

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		39	47
NORTH WEST	0-19	*	*	0
	20-34	*	*	9
	35-49	*	*	17
	50+	*	*	29
	Total HSDA:		69	107
NORTHERN INTERIOR	0-19	6	6	*
	20-34	18	21	*
	35-49	70	86	*
	50+	85	142	*
	Total HSDA:		179	255
Total HA:		287	409	202

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	8	8	*
	20-34	31	36	*
	35-49	108	143	*
	50+	140	222	*
Total HA:		287	409	202

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	175	253	124
Female	112	156	78

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	202	50	560	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	17	8
	5 years or more	14	7
	<5 years	8	6
	Total HSDA:	39	21
NORTH WEST	10 years or more	30	19
	5 years or more	26	24
	<5 years	13	12
	Total HSDA:	69	55
NORTHERN INTERIOR	10 years or more	71	49
	5 years or more	61	46
	<5 years	47	31
	Total HSDA:	179	126
Total HA:		287	202

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	118	76
	5 years or more	101	77
	<5 years	68	49
Total HA:		287	202

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	38	61	8	8
NORTH WEST	70	158	15	28
NORTHERN INTERIOR	103	446	15	179
Total:	211	665	38	215

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	6
NORTH WEST	20
NORTHERN INTERIOR	17
Total:	43

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	6	10	5
	KOOTENAY BOUNDARY	6	9	6
	OKANAGAN	22	37	14
	THOMPSON/CARIBOO/SHUSWAP	26	44	19
	Total HA:	60	100	44
FRASER	FRASER EAST	42	52	32
	FRASER NORTH	54	90	43
	FRASER SOUTH	69	102	52
	Total HA:	165	244	127
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	25	48	24
	RICHMOND	12	17	9
	VANCOUVER	501	849	403
	Total HA:	538	914	436
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	51	79	42
	NORTH VANCOUVER ISLAND	15	24	13
	SOUTH VANCOUVER ISLAND	35	77	29
	Total HA:	101	180	84
NORTHERN	NORTH EAST	10	12	7
	NORTH WEST	33	62	29
	NORTHERN INTERIOR	62	99	45
	Total HA:	105	173	81
Total:		969	1611	772

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	605	1028	477
Female	364	583	295

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	772	51	500	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.





Descovy (DSC): the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay, DTG): an INTEGRASE INHIBITOR from ViiV Healthcare.

Efavirenz (Sustiva, Auro efavirenz, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine (FTC): a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intence, ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya (GNV): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

Maraviroc (Celsentri, MVC): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by





blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

NRTI: see NUCLEOSIDE ANALOG.

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

Odefsey (ODF): the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant, RPV): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq (TRQ): the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.





Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

